Key points are not available for this paper at this time.
Polypharmacy associates with >4 diagnoses in AECOPD inpatients; leaves open whether deprescribing improves outcomes in this population.
Chronic obstructive pulmonary disease (COPD) imposes a great burden on health systems, and the expense will increase in the years to come [1]. Medication represents a large proportion of COPD-related costs [2], and has increased by 170% over the past 20 years [3]. Inpatients with an acute exacerbation of COPD and more than four diagnoses after admission are prescribed significantly more drugs and present with polypharmacy more frequently [4]...
No takes yet. Share an insight, caveat, or question.
Díez‐Manglano et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: